Cite
HARVARD Citation
Wei, X. et al. (2018). A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer. Oncologist. pp. 656-e64. [Online].